Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06975189

MINImising Total Radiation EXposure in Preterm Infants

Being born too early (preterm birth) is the leading cause of death in children world-wide. In Australia, 97% of very preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth to survive. Despite this significant global impact, neonatal clinicians have few tools available to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is a chest X-ray. To reduce radiation exposure, chest X-rays are usually only performed one or two times a day. As chronic lung disease in babies who survive preterm birth is increasing, there is an urgent need to develop new ways to monitor the lungs of these fragile babies.

Lung ultrasound is a form of imaging that is fast, gentle and radiation free. However, it has not been routinely adopted into caring for preterm babies in most countries. This is because there are no randomised controlled trials that have demonstrated the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. The investigators will conduct a randomised controlled trial to demonstrate that lung ultrasound is a quick, safe and accurate alternative to chest x-rays in preterm babies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 24 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Joan Kirner Women's and Children's, Sunshine Hospital, Western Health

Melbourne, Victoria, 3021, Australia

Location status: Recruiting

Location contact

Aun Sett, MBBS CCPU FRACP PhD

CONTACT

[email protected]

+6190552463

About this study

Preterm babies are born with underdeveloped, fragile lungs and commonly develop respiratory distress syndrome. In Australia, 97% of preterm babies who are admitted to Neonatal Intensive Care Units need breathing support after birth. Respiratory support is vital to keep babies alive but is associated with short- and long-term lung damage. Unfortunately, many babies who survive preterm birth develop bronchopulmonary dysplasia (BPD), leading to poor health outcomes in adulthood.(2) Despite years of research, chronic lung disease is increasing.

Clearly, it is critical that clinicians have effective tools to guide breathing support. Currently, the only lung imaging tool that is routinely used in the Neonatal Intensive Care Unit is chest X-ray (CXR). The fundamental principle of use of ionising radiation in any population is to limit radiation exposure to as low as reasonably achievable (ALARA). To achieve this currently, the use of CXR is usually limited to once or twice a day. In addition CXR are performed by a specialised technician and are not always immediately available, delaying the time to diagnosis. Given the rapid and unpredictable changes in a preterm baby's lung disease, reliance on repeated CXR is fraught with risk. There is an urgent need to develop reliable tools that provides real-time and accurate feedback to guide breathing support in preterm babies.

New monitoring tools should be safe and improve outcomes. Lung ultrasound is a gentle form of lung imaging that is ideally suited for preterm babies. It is radiation free, readily available and does not require excessive handling of the baby. Ultrasound is already routinely used to image the brain and hearts of preterm babies and systems are available in all Neonatal Intensive Care Units in Australia. Several observational studies have demonstrated that lung ultrasound is accurate in diagnosing common neonatal respiratory disorders including pneumothorax, respiratory distress syndrome, transient tachypnoea of the newborn and the need for mechanical ventilation. Not all features of lung ultrasound are interchangeable with CXR measures of lung aeration in preterm infants. Lung ultrasound has a stronger relationship with an infant's respiratory support requirements than CXR. Only one study to date has assessed the ability of lung ultrasound to guide surfactant replacement in a randomized setting. Despite the growing body of evidence that lung ultrasound may be a suitable alternative to CXR, it has not been routinely adopted into clinical practice. This is because no randomized controlled trial has assessed the benefit and safety of using lung ultrasound as the first-line imaging tool in preterm babies. Furthermore, despite no evidence of benefit, some centres have already implemented lung ultrasound into routine practice. Before lung ultrasound can be widely implemented in preterm babies, it must be demonstrated to be beneficial and safe.

The investigators hypothesise that in preterm babies born <32 weeks' gestation, lung ultrasound will significantly reduce radiation exposure and be a safe alternative to CXR. This will be addressed by conducting an open label, randomised controlled trial at Joan Kirner Women's and Children's, Sunshine Hospital, Victoria.

The primary aim of this study is to evaluate whether the use of lung ultrasound as the primary lung imaging modality in preterm babies born <32 weeks' gestation reduces radiation burden.

Secondary aims include assessment of the safety and acceptability of lung ultrasound as the first line imaging tool, and additional signals of benefit including time to receive lung imaging and initiation of treatment, and duration of breathing support. To assess safety, the investigators will report the rate of key protocol defined adverse and serious adverse events in the intervention and control groups. Feasibility will be determined by protocol defined criteria for operational and clinical feasibility. Cost effectiveness will be determined by reporting the microcosts of each imaging tool and comparing the differential costs between the lung ultrasound and chest X-ray. Finally, the investigators will assess the acceptability to neonatal healthcare workers of lung ultrasound as the first-line imaging tool.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All infants born <32 weeks' gestation and admitted to the neonatal intensive care unit (NICU) who require lung imaging for respiratory indications will be considered eligible. Each infant must meet all the following criteria to be enrolled in this study:

  • The infant is born from 22 to 31+6 weeks' gestation by best obstetric estimate and admitted to the NICU
  • The infant is considered to require lung imaging for respiratory indications
  • The infant has a parent/guardian who can provide informed consent.

Exclusion criteria

  • The infant will only require CXR to be performed solely to confirm device position i.e. central line, endotracheal tube, gastric tubes
  • The infant will only require CXR to be performed for specifically for non-respiratory indications i.e. assessment of cardiac silhouette
  • The infant's Clinician has concern regarding clinical stability and tolerability of ultrasound scans
  • The infant's skin integrity will not tolerate ultrasound gel
  • Refusal of informed consent by their parent/guardian/legally acceptable representative
  • The infant does not have a parent/guardian who can provide informed consent.

Treatment and study plan

Lung ultrasound group

Device

Infants in the intervention arm will receive lung ultrasound as their first line imaging. Clinicians will be permitted to order a chest x-ray if they require further information or if the lung ultrasound findings are inconclusive or not consistent with the clinical findings.

Standard care

Diagnostic Test

Infants in the standard group will receive chest X-ray as their first line imaging tool. Lung ultrasound will not be permitted in this group.

Primary outcomes

  1. The mean difference in number of x-rays and radiation exposure in the intervention group

    Time frame: Until day 14 of life

    The total number of chest X-rays performed in the study period

Secondary outcomes

  1. The mean difference of X-rays for entire admission (until discharge or death)

    Time frame: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 12 months

    Total number of x-rays performed from enrolment in study until death or discharge from hospital

  2. The mean difference of X-rays and radiation exposure by gestational age at birth

    Time frame: Until day 14 of life

    The total number of CXR performed in the study period stratified by gestational groups (< 28 weeks' gestation and >/= to 28 weeks' gestation)

  3. Time to administering surfactant if clinically indicated

    Time frame: Until day 14 of life

    The mean difference in minutes to administer surfactant if clinically indicted between the lung ultrasound and chest x-ray groups

  4. Proportion of infants in the intervention arm who require CXR as first-line imaging due to lung ultrasound not being available

    Time frame: Until day 14 of life

    The number of CXRs performed after a lung ultrasound is performed in the intervention group due to the ultrasound clinicians or system not being available.

  5. Cost-effectiveness

    Time frame: Until day 14 of life

    The differential costs between the intervention and control groups determine from a time-in-motion analysis of a pre-determined sub sample of the study population (n=10 patients per group)

Other outcomes

  1. Serious adverse event [1]

    Time frame: During or within 1 hour after each scheduled lung imaging assessment

    Oxygen requirement of fraction of inspired oxygen (FiO2) ≥20% of baseline for 2 hours or more after the lung imaging assessment

  2. Serious adverse event [2]

    Time frame: During or within 1 hour after each scheduled lung imaging assessment

    Acute oxygen desaturation (peripheral oxygen saturations [SpO2] <90%) that required the lung imaging to be terminated

  3. Serious adverse event [3]

    Time frame: During or within 1 hour after each scheduled lung imaging assessment

    Requirement of escalation of respiratory support

  4. Serious adverse event [4]

    Time frame: During or within 1 hour after each scheduled lung imaging assessment

    Apnoea requiring stimulation or other intervention that required the lung imaging to be terminated

  5. Serious adverse event [5]

    Time frame: Within 1 hours of each scheduled lung imaging assessment a photograph of the area will be taken and blindly scored using Hume-T scoring system

    For infants born <24 weeks' gestation, breech of skin integrity or skin irritation associated with lung imaging within 1 hour of imaging episode

  6. Serious adverse event [6]

    Time frame: From the date of randomisation until 14 days

    Allocated imaging not being available and alternative imaging required

  7. Adverse event [1]

    Time frame: During or within 24 hours after each scheduled lung imaging assessment

    Any death

  8. Adverse event [2]

    Time frame: During or within 24 hours after each scheduled lung imaging assessment

    Pulmonary haemorrhage

  9. Adverse event [3]

    Time frame: During or within 24 hours after each scheduled lung imaging assessment

    Administration of epinephrine or use of chest compressions

  10. Adverse event [4]

    Time frame: During or within 1 hour after each scheduled lung imaging assessment

    Unplanned extubation

  11. Adverse event [5]

    Time frame: Within first 2 weeks of age

    In the intervention group, a significant delay in diagnosis and initiation of appropriate intervention for the following conditions due to lung ultrasound being inconclusive and a CXR being required to confirm diagnosis as determined by the clinical team:

    • Significant pneumothorax
    • Significant pleural effusion
    • Severe respiratory distress syndrome requiring surfactant replacement therapy
  12. Duration and level of mechanical ventilation and/or other respiratory support

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 12 months

    Days of supplemental oxygen

  13. Duration of invasive and non invasive ventilation

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 12 months

    Days of respiratory support including mechanical ventilation, continuous positive airway pressure and nasal high flow therapy

  14. Post natal corticosteroid use

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 12 months

    Use of postnatal steroids, including types, timing and accumulated doses

  15. Incidence of Air leak

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Incidence of pulmonary interstitial emphysema or pneumothorax

  16. Use of Volume expansion (crystalloid or colloid)

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Total amount of volume expansion (in ml/kg) given during study duration

  17. Use of inotropic support

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Maximum level of inotropic support given (drug and dose) during study duration

  18. Blood transfusion administration

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Total blood transfused in ml/kg during study duration

  19. Incidence of patent ductus arteriosus

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Incidence of patent ductus arteriosus requiring medical or surgical treatment during study duration

  20. Incidence of retinopathy of prematurity

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 6 months

    Incidence of retinopathy of prematurity stratified by grade

  21. Incidence of necrotising enterocolitis

    Time frame: From date of randomisation until death or 2 weeks of age, whichever comes first, 2 weeks

    Incidence of Stage 2 or higher necrotising enterocolitis for study duration

  22. Incidence of intraventricular haemorrhage (IVH)

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 6 months

    Incidence of IVH over entire admission

  23. Incidence of periventricular leukomalacia (PVL)

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 12 months

    Incidence of PVL during entire admission

  24. Duration of admission

    Time frame: From date of randomisation until death or discharge, whichever comes first, maximum 12 months

    Duration of entire hospital admission u

  25. Diagnosis of BPD at 36 weeks

    Time frame: From date of randomisation until death or discharge or 36 weeks post menstrual age, whichever comes first, maximum 36 weeks

    BPD status at 36 weeks defined by the standard oxygen reduction (ORT) test

  26. Death

    Time frame: From date of randomisation until death or discharge or 36 weeks post menstrual age, whichever comes first, maximum 6 months

    Survival status/date of death during hospital stay / cause and location of death

Study contacts

Contact information is provided by the study sponsor or research team.

Arun Sett, PhD

CONTACT

[email protected]

+61405491595

Niranjan Abraham, MD

CONTACT

[email protected]

0413751479

Sponsors and collaborators

Lead sponsor

Western Health, Australia

Other Gov

Registry information

Official study title

Lung Ultrasound to Reduce the Number of Chest X-rays in Very Preterm Infants in the First 2 Weeks After Birth: A Randomised Controlled Trial

Acronym: MINI T-Rex

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
May 16, 2025
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.